Robert Bristow

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6488764/publications.pdf

Version: 2024-02-01

250 papers	18,945 citations	9775 73 h-index	14736 127 g-index
265 all docs	265 docs citations	265 times ranked	23548 citing authors

#	Article	IF	Citations
1	Hypoxia, DNA repair and genetic instability. Nature Reviews Cancer, 2008, 8, 180-192.	12.8	991
2	Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy. Radiation Research, 2010, 173, 719.	0.7	547
3	Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics, 2019, 51, 308-318.	9.4	480
4	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities. Molecular Cell, 2014, 53, 7-18.	4.5	466
5	Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017, 541, 359-364.	13.7	462
6	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
7	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	9.4	395
8	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	9.4	380
9	Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner. Molecular and Cellular Biology, 2002, 22, 6521-6532.	1.1	354
10	Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. Molecular and Cellular Biology, 2004, 24, 8504-8518.	1.1	341
11	Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell, 2019, 176, 831-843.e22.	13.5	317
12	Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs. Cancer Research, 2005, 65, 11597-11604.	0.4	313
13	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	5.1	291
14	Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance. Cancer Research, 2008, 68, 605-614.	0.4	286
15	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
16	Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical Cancer Research, 2013, 19, 6741-6750.	3.2	268
17	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	0.8	241
18	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	6.3	240

#	Article	IF	Citations
19	Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 2108-2114.	3.2	233
20	Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment. Cancer Research, 2010, 70, 8045-8054.	0.4	211
21	Germline MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study. Gastroenterology, 2009, 136, 1251-1260.	0.6	197
22	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics, 2016, 48, 1142-1150.	9.4	196
23	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018, 34, 996-1011.e8.	7.7	190
24	The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology, 1996, 40, 197-223.	0.3	185
25	MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. Cancer Research, 2010, 70, 7017-7026.	0.4	184
26	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications, 2017, 8, 13671.	5.8	182
27	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
28	Tumor hypoxia as a driving force in genetic instability. Genome Integrity, 2013, 4, 5.	1.0	181
29	Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells. International Journal of Radiation Oncology Biology Physics, 2010, 78, 221-229.	0.4	177
30	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell, 2018, 173, 1003-1013.e15.	13.5	176
31	Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology, 2005, 76, 168-176.	0.3	172
32	T1/T2 Glottic Cancer Managed by External Beam Radiotherapy: The Influence of Pretreatment Hemoglobin on Local Control. International Journal of Radiation Oncology Biology Physics, 1998, 41, 347-353.	0.4	169
33	The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell, 2019, 35, 414-427.e6.	7.7	168
34	Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. Journal of Cell Biology, 2006, 175, 55-66.	2.3	166
35	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	2.1	161
36	TMPRSS2â€"ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics, 2017, 49, 1336-1345.	9.4	161

#	Article	IF	Citations
37	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	5.8	143
38	A Prostate Cancer â€œ Nimbosus â€� Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674.	0.9	142
39	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.4	139
40	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	2.7	132
41	Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents. Journal of Clinical Oncology, 2003, 21, 2760-2776.	0.8	131
42	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology, 2008, 88, 258-268.	0.3	130
43	miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1. Cancer Research, 2013, 73, 6972-6986.	0.4	127
44	Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets. Seminars in Radiation Oncology, 2010, 20, 274-281.	1.0	123
45	Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?. Radiotherapy and Oncology, 2017, 124, 344-356.	0.3	122
46	<i>PTEN</i> Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. Clinical Cancer Research, 2012, 18, 1015-1027.	3.2	119
47	The p53 protein family and radiation sensitivity: Yes or no?. Cancer and Metastasis Reviews, 2004, 23, 237-257.	2.7	116
48	Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. Journal of Experimental Medicine, 2010, 207, 983-997.	4.2	112
49	MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle, 2011, 10, 2218-2232.	1.3	111
50	Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. Cancer Research, 2007, 67, 6022-6025.	0.4	109
51	Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells. Cancer Research, 2004, 64, 8526-8533.	0.4	108
52	Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. Journal of Cell Science, 2012, 125, 189-199.	1.2	108
53	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	5.1	108
54	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 85-94.	0.8	107

#	ARTICLE	IF	CITATIONS
55	The MMS22L-TONSL Complex Mediates Recovery from Replication Stress and Homologous Recombination. Molecular Cell, 2010, 40, 619-631.	4.5	106
56	Copy number alterations of <i>câ€MYC</i> and <i>PTEN</i> are prognostic factors for relapse after prostate cancer radiotherapy. Cancer, 2012, 118, 4053-4062.	2.0	105
57	Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer. International Journal of Radiation Biology, 2009, 85, 805-813.	1.0	101
58	Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases. ACS Nano, 2013, 7, 4221-4232.	7.3	101
59	â€œContextualâ€•Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair. Clinical Cancer Research, 2010, 16, 4553-4560.	3.2	100
60	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	5.8	100
61	Direct observation of ultrafast-electron-transfer reactions unravels high effectiveness of reductive DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11778-11783.	3.3	99
62	A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiotherapy and Oncology, 2004, 70, 37-44.	0.3	98
63	Evidence for the Direct Binding of Phosphorylated p53 to Sites of DNA Breaks In vivo. Cancer Research, 2005, 65, 10810-10821.	0.4	98
64	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 303-309.	0.8	98
65	Radiation and New Molecular Agents Part I: Targeting ATM-ATR Checkpoints, DNA Repair, and the Proteasome. Seminars in Radiation Oncology, 2006, 16, 51-58.	1.0	97
66	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular Cancer Therapeutics, 2009, 8, 203-213.	1.9	95
67	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer, 2018, 18, 8.	1.1	93
68	Divergent mutational processes distinguish hypoxic and normoxic tumours. Nature Communications, 2020, 11, 737.	5.8	90
69	Characterization of Mutant MUTYH Proteins Associated With Familial Colorectal Cancer. Gastroenterology, 2008, 135, 499-507.e1.	0.6	89
70	Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair. Cancer Research, 2010, 70, 8748-8759.	0.4	84
71	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget, 2015, 6, 1900-1919.	0.8	80
72	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	3.0	76

#	Article	IF	Citations
73	Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncology, 2007, 3, 329-341.	1.1	75
74	Highâ€resolution array CGH identifies novel regions of genomic alteration in intermediateâ€risk prostate cancer. Prostate, 2009, 69, 1091-1100.	1.2	75
75	Changes in apparent diffusion coefficient and T₂ relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging, 2013, 37, 909-916.	1.9	74
76	Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget, 2017, 8, 4668-4689.	0.8	74
77	Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology, 2011, 6, 144.	1.2	73
78	Hypoxia and Predicting Radiation Response. Seminars in Radiation Oncology, 2015, 25, 260-272.	1.0	73
79	Alterations in DNA Repair Gene Expression under Hypoxia: Elucidating the Mechanisms of Hypoxia-Induced Genetic Instability. Annals of the New York Academy of Sciences, 2005, 1059, 184-195.	1.8	69
80	DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio. Seminars in Radiation Oncology, 2010, 20, 217-222.	1.0	68
81	Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiotherapy and Oncology, 2007, 83, 220-230.	0.3	67
82	Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Molecular Cancer Therapeutics, 2008, 7, 993-999.	1.9	66
83	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. Journal of Pathology, 2012, 227, 53-61.	2.1	63
84	Association Between Germline HOXB13 G84E Mutation and Risk of Prostate Cancer. Journal of the National Cancer Institute, 2012, 104, 1260-1262.	3.0	62
85	Hypoxia and Cellular Localization Influence the Radiosensitizing Effect of Gold Nanoparticles (AuNPs) in Breast Cancer Cells. Radiation Research, 2014, 182, 475-488.	0.7	62
86	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	5.8	60
87	Late Residual Î³-H2AX Foci In Murine Skin are Dose Responsive and Predict Radiosensitivity<i>In Vivo</i>. Radiation Research, 2010, 173, 1-9.	0.7	59
88	Treatment of radiation proctitis with hyperbaric oxygen. Radiotherapy and Oncology, 2006, 78, 91-94.	0.3	57
89	Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology, 2009, 4, 50.	1.2	57
90	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 57726-57736.	0.8	55

#	Article	IF	Citations
91	Synergistic Nanoparticulate Drug Combination Overcomes Multidrug Resistance, Increases Efficacy, and Reduces Cardiotoxicity in a Nonimmunocompromised Breast Tumor Model. Molecular Pharmaceutics, 2014, 11, 2659-2674.	2.3	54
92	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell, 2020, 80, 562-577.	4.5	54
93	Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity. Clinical Cancer Research, 2009, 15, 5576-5583.	3.2	53
94	The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews Urology, 2019, 16, 281-290.	1.9	53
95	A Cinematic Magnetic Resonance Imaging Study of Milk of Magnesia Laxative and an Antiflatulent Diet to Reduce Intrafraction Prostate Motion. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1072-1078.	0.4	52
96	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e441-e448.	0.4	52
97	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell, 2019, 36, 674-689.e6.	7.7	52
98	Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy. Cancer, 2005, 104, 891-905.	2.0	51
99	Microscopic imaging of DNA repair foci in irradiated normal tissues. International Journal of Radiation Biology, 2009, 85, 732-746.	1.0	51
100	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 3818-3829.	3.2	51
101	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications, 2020, 11, 441.	5.8	51
102	AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells. International Journal of Radiation Oncology Biology Physics, 2012, 84, e507-e514.	0.4	50
103	A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. International Journal of Radiation Biology, 2011, 87, 1120-1125.	1.0	49
104	ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics, 2014, 15, 78.	1.2	49
105	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiotherapy and Oncology, 2015, 116, 486-494.	0.3	48
106	Hypoxia Provokes Base Excision Repair Changes and a Repair-Deficient, Mutator Phenotype in Colorectal Cancer Cells. Molecular Cancer Research, 2014, 12, 1407-1415.	1.5	47
107	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. Prostate, 2015, 75, 1277-1284.	1.2	47
108	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature Medicine, 2019, 25, 1615-1626.	15.2	45

#	Article	IF	Citations
109	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. Radiation Research, 2017, 187, 147-160.	0.7	44
110	<i>NKX3.1</i> Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy. Clinical Cancer Research, 2012, 18, 308-316.	3.2	43
111	Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle, 2012, 11, 1432-1444.	1.3	43
112	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews Urology, 2015, 12, 193-204.	1.9	41
113	MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy. Radiology, 2015, 274, 181-191.	3.6	40
114	Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells. Radiotherapy and Oncology, 2012, 102, 459-465.	0.3	39
115	<i>TMPRSS2-ERG</i> Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209.	3.2	39
116	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. Journal of Clinical Investigation, 2012, 122, 4025-4036.	3.9	39
117	Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. Oncogene, 1998, 16, 1789-1802.	2.6	38
118	Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Medical Genetics, 2008, 9, 69.	2.1	38
119	Comment on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis" (II). Science, 2003, 302, 1894d-1894.	6.0	37
120	Novel Chemical Enhancers of Heat Shock Increase Thermal Radiosensitization through a Mitotic Catastrophe Pathway. Cancer Research, 2007, 67, 695-701.	0.4	37
121	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 174.	2.4	37
122	Linking the History of Radiation Biology to the Hallmarks of Cancer. Radiation Research, 2014, 181, 561-577.	0.7	37
123	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology, 2017, 72, 22-31.	0.9	37
124	Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer and Metastasis Reviews, 2008, 27, 445-458.	2.7	36
125	PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and Oncology, 2008, 86, 407-411.	0.3	36
126	Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiotherapy and Oncology, 2011, 101, 190-197.	0.3	36

#	Article	IF	Citations
127	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 84-91.	0.4	36
128	Tumor Hypoxia as a Modifier of DNA Strand Break and Cross-Link Repair. Current Molecular Medicine, 2009, 9, 401-410.	0.6	34
129	Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Cometâ€"FISH. Breast Cancer Research and Treatment, 2005, 91, 89-94.	1.1	33
130	Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome. Journal of the National Cancer Institute, 2020, 112, 247-255.	3.0	33
131	Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta OncolÃ³gica, 2010, 49, 888-894.	0.8	32
132	Education and Training for Radiation Scientists: Radiation Research Program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12â€"14, 2003. Radiation Research, 2003, 160, 729-737.	0.7	31
133	Patient-specific PTV margins in radiotherapy for bladder cancer â€" A feasibility study using cone beam CT. Radiotherapy and Oncology, 2011, 99, 131-136.	0.3	31
134	The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiotherapy and Oncology, 2011, 101, 59-65.	0.3	31
135	Electron transfer-based combination therapy of cisplatin with tetramethyl- <i>p</i> -phenylenediamine for ovarian, cervical, and lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10175-10180.	3.3	31
136	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.3	30
137	Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination. Cancer Research, 2013, 73, 1611-1620.	0.4	30
138	<i>NBN</i>gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget, 2014, 5, 11081-11090.	0.8	30
139	High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International Journal of Cancer, 2014, 135, 1692-1699.	2.3	29
140	Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. Radiation Research, 2016, 185, 549.	0.7	29
141	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 38-45.	0.9	29
142	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 107-113.	12.5	28
143	Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy. Prostate, 2016, 76, 1169-1181.	1.2	28
144	Intratumoral Hypoxia as the Genesis of Genetic Instability and Clinical Prognosis in Prostate Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 189-204.	0.8	28

#	Article	IF	Citations
145	Recurrent prostate cancer following external beam radiotherapy. Urologic Clinics of North America, 2003, 30, 751-763.	0.8	27
146	Investigations of antioxidant-mediated protection and mitigation of radiation-induced DNA damage and lipid peroxidation in murine skin. International Journal of Radiation Biology, 2013, 89, 618-627.	1.0	26
147	Current Status and Recommendations for the Future ofÂResearch, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary. International Journal of Radiation Oncology Biology Physics, 2014, 88, 11-17.	0.4	26
148	A randomized comparison of interfraction and intrafraction prostate motion with and without abdominal compression. Radiotherapy and Oncology, 2008, 88, 88-94.	0.3	25
149	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e415-e421.	0.4	25
150	MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS ONE, 2016, 11, e0165214.	1.1	25
151	Prostate zones and cancer: lost in transition?. Nature Reviews Urology, 2022, 19, 101-115.	1.9	25
152	ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. Radiotherapy and Oncology, 2011, 99, 307-312.	0.3	24
153	Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Laboratory Investigation, 2013, 93, 397-407.	1.7	24
154	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology, 2015, 5, e473-e482.	1.1	24
155	Resistance to Bleomycin in Cancer Cell Lines Is Characterized by Prolonged Doubling Time, Reduced DNA Damage and Evasion of G2/M Arrest and Apoptosis. PLoS ONE, 2013, 8, e82363.	1.1	23
156	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 195-204.	1.1	23
157	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology, 2017, 122, 93-98.	0.3	23
158	Bad neighbours: hypoxia and genomic instability in prostate cancer. British Journal of Radiology, 2020, 93, 20200087.	1.0	23
159	Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53. Oncogene, 2003, 22, 2960-2966.	2.6	22
160	Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate, 2005, 65, 124-129.	1.2	22
161	Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Scientific Reports, 2017, 7, 595.	1.6	22
162	Lost in application: Measuring hypoxia for radiotherapy optimisation. European Journal of Cancer, 2021, 148, 260-276.	1.3	21

#	Article	IF	Citations
163	Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers. PLoS ONE, 2015, 10, e0121872.	1.1	21
164	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology, 2016, 6, 24.	1.3	20
165	BAMQL: a query language for extracting reads from BAM files. BMC Bioinformatics, 2016, 17, 305.	1.2	20
166	Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. Journal of Molecular Cell Biology, 2013, 5, 428-431.	1.5	19
167	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy caseâ€"control study with multicohort validation. PLoS Medicine, 2020, 17, e1003281.	3.9	19
168	Expression of Different Mutant p53 Transgenes in Neuroblastoma Cells Leads to Different Cellular Responses to Genotoxic Agents. Experimental Cell Research, 2002, 275, 122-131.	1.2	18
169	Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS ONE, 2016, 11, e0167272.	1.1	18
170	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology, 2017, 123, 459-465.	0.3	18
171	Use of Sequenom Sample ID PlusÂ® SNP Genotyping in Identification of FFPE Tumor Samples. PLoS ONE, 2014, 9, e88163.	1.1	17
172	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.3	17
173	Radiation Effects and Radioprotection in MC3T3-E1 Mouse Calvarial Osteoblastic Cells. Plastic and Reconstructive Surgery, 2008, 122, 1025-1035.	0.7	16
174	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. Current Problems in Cancer, 2017, 41, 265-272.	1.0	16
175	Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. PLoS ONE, 2018, 13, e0194809.	1.1	16
176	WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Molecular Cancer Therapeutics, 2008, 7, 980-992.	1.9	15
177	Protein-Protein Interactions Occur Between p53 Phosphoforms and ATM and 53BP1 at Sites of Exogenous DNA Damage. Radiation Research, 2011, 175, 588.	0.7	15
178	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. Clinical Cancer Research, 2016, 22, 3124-3126.	3.2	15
179	The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. European Journal of Cancer, 2020, 131, 76-88.	1.3	15
180	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications, 2021, 12, 6248.	5.8	15

#	Article	IF	Citations
181	Neoplastic cell response to tiopronin-coated gold nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 264-273.	1.7	14
182	PMH 9907: Longâ€term outcomes of a randomized phase 3 study of shortâ€term bicalutamide hormone therapy and doseâ€escalated externalâ€beam radiation therapy for localized prostate cancer. Cancer, 2016, 122, 2595-2603.	2.0	14
183	Intraductal Carcinoma of the Prostate: Anonymous to Ominous. European Urology, 2017, 72, 496-498.	0.9	14
184	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	0.6	14
185	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	13
186	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology, 2020, , .	2.6	13
187	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2011, 5, e31-e35.	0.3	13
188	Recommendations for the future of translational radiobiology research: a Canadian perspective. Radiotherapy and Oncology, 2004, 70, 159-164.	0.3	12
189	Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer and Metastasis Reviews, 2008, 27, 375-385.	2.7	12
190	<i>In Vitro</i> and <i>In Vivo</i> Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer. Molecular Cancer Therapeutics, 2016, 15, 640-650.	1.9	12
191	P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. International Journal of Radiation Oncology Biology Physics, 1996, 34, 341-355.	0.4	11
192	Biodosimetry using radiation-induced micronuclei in skin fibroblasts. International Journal of Radiation Biology, 2011, 87, 824-838.	1.0	10
193	Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 608-616.	0.4	10
194	Allelic loss of the loci containing the androgen synthesis gene, <i>StAR</i>, is prognostic for relapse in intermediateâ€risk prostate cancer. Prostate, 2012, 72, 1295-1305.	1.2	10
195	SeqControl: process control for DNA sequencing. Nature Methods, 2014, 11, 1071-1075.	9.0	10
196	Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. Radiotherapy and Oncology, 2017, 124, 427-432.	0.3	10
197	Basis of Cell Kill Following Clinical Radiotherapy. , 2005, , 293-320.		10
198	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget, 2017, 8, 87638-87646.	0.8	10

#	Article	IF	Citations
199	Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie!. Breast Cancer Research, 2010, 12, 111.	2.2	9
200	Clonality of localized and metastatic prostate cancer. Current Opinion in Urology, 2016, 26, 219-224.	0.9	9
201	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist, 2017, 22, 152-157.	1.9	9
202	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology, 2017, 71, 748-749.	0.9	9
203	Comparison of pre-processing methods for Infinium HumanMethylation450 BeadChip array. Bioinformatics, 2017, 33, 3151-3157.	1.8	9
204	Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells. Radiotherapy and Oncology, 2015, 116, 388-391.	0.3	8
205	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.4	8
206	The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. Lancet Oncology, The, 2020, 21, 17-19.	5.1	8
207	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. NAR Cancer, 2020, 2, zcaa012.	1.6	8
208	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
209	Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts. Radiotherapy and Oncology, 2022, 170, 213-223.	0.3	8
210	Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. Canadian Urological Association Journal, 2014, 8, 783.	0.3	7
211	Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Practical Radiation Oncology, 2014, 4, 323-329.	1.1	7
212	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology, 2017, 12, 50.	1.2	7
213	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. Cancer Research, 2021, 81, 5833-5848.	0.4	7
214	The telomere length landscape of prostate cancer. Nature Communications, 2021, 12, 6893.	5.8	7
215	4FISH-IF, a Four-Color Dual-Gene FISH Combined with p63 Immunofluorescence to Evaluate <i>NKX3.1</i> and <i>MYC</i> Status in Prostate Cancer. Journal of Histochemistry and Cytochemistry, 2013, 61, 500-509.	1.3	5
216	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. BMC Urology, 2021, 21, 96.	0.6	5

#	Article	IF	Citations
217			

#	Article	IF	Citations
235	Biology of Cancer. , 2008, , 3-22.		1
236	Imaging radiation biology for optimised radiation therapy. International Journal of Radiation Biology, 2009, 85, 729-731.	1.0	1
237	IMRT and molecular biological approaches in radiotherapy for prostate cancer. European Journal of Cancer, 2009, 45, 429-430.	1.3	1
238	Introduction: DNA Repair and Radiotherapy Targeting: An Overview. Seminars in Radiation Oncology, 2010, 20, 215-216.	1.0	1
239	Response to â€œIntraoperative Radiotherapy During Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical and Dosimetric Aspectsâ€•(Int J Radiat Oncol Biol PhysÂ2009; in press). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1277.	0.4	1
240	Prostate Cancer Genomics as a Driver of Personalized Medicine. , 2014, , 233-245.		1
241	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. Journal of Clinical Oncology, 2016, 34, e80-e83.	0.8	1
242	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 702-709.	0.4	1
243	A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer. European Urology, 2018, 73, 533-534.	0.9	1
244	RNF8-Independent Lys63 Poly-Ubiquitylation Prevents Genomic Instability in Response to Replication-Associated DNA Damage. PLoS ONE, 2014, 9, e89997.	1.1	1
245	Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy. Canadian Journal of Urology, 2006, 13 Suppl 2, 63-7.	0.0	1
246	In Reply to Nieder. International Journal of Radiation Oncology Biology Physics, 2013, 85, 581.	0.4	0
247	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2013, 5, 31.	0.3	0
248	Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality. Cancer Drug Discovery and Development, 2015, , 345-361.	0.2	0
249	Response. Journal of the National Cancer Institute, 2017, 109, .	3.0	0
250	Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. Journal of Cell Biology, 2010, 189, i6-i6.	2.3	0